# First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

> **NCT03693677** · PHASE2 · COMPLETED · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 288 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Irinotecan Liposomal Injection
- **DRUG:** 5-FU/LV
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03693677
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-16
- **Primary completion:** 2025-01-10
- **Final completion:** 2025-01-10
- **Target enrollment:** 288 (ACTUAL)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03693677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03693677, "First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT03693677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*